Download PDF
Dtsch Med Wochenschr 2011; 136(40): 2045-2049
DOI: 10.1055/s-0031-1286392
Prävention & Versorgungsforschung | Review article
Versorgungsforschung, Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Prävention des Schlaganfalls durch Blutdrucksenkung

Prevention of stroke by blood pressure loweringJ. Schrader1 , S. Lüders1
  • 1St. Josefs-Hospital Cloppenburg
Further Information

Publication History

eingereicht: 28.7.2011

akzeptiert: 21.9.2011

Publication Date:
28 September 2011 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Hypertonie - Schlaganfall - antihypertensive Therapie - Prävention - Blutdruckvariabilität - Zielblutdruck

Keywords

hypertension - stroke - antihypertensive therapy - prevention - blood pressure variability - target blood pressure

Literatur

  • 1 Beckett N S, Peters R, Fletscher A E. et al . Treatment of hypertension in patients 80 years of age or older.  N Engl J Med. 2008;  358 1887-1898
    Google Scholar
  • 2 Cushman W C, Evans G W. et al . ACCORD Study Group: Effects of intensive blodd-pressure control in type 2 diabetes mellitus.  N Engl J Med. 2010;  362 1575-1595
    Google Scholar
  • 3 Dahlöf B, Sever P S, Poulter N R. et al . Prevention of cardiovaskular events with an an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial.  Lancet. 2005;  366 895-906
    Google Scholar
  • 4 Deutsche Hochdruckliga e. V. DHL® – Deutsche Hypertonie Gesellschaft: Leitlinien zur Therapie der arteriellen Hypertonie. Heidelberg; 2008
    Google Scholar
  • 5 Elliot W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 201-207
    Google Scholar
  • 6 Eriksson S E, Olsson J E. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study.  Cerebrovasc Dis. 2001;  12 171-180
    Google Scholar
  • 7 Giles M F, Rothwell P M. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis.  Lancet Neurol. 2007;  6 1063-1072
    Google Scholar
  • 8 Lindholm L H, Carlberg B, Samuelssson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.  Lancet. 2005;  366 1545-1553
    Google Scholar
  • 9 Lüders S. Drug therapy for the secondary prevention of stroke in hypertensive patients. Current issues and options.  Drugs. 2007;  67 955-963
    Google Scholar
  • 10 MacMahon S, Rodgers A. Primary and secondary prevention of stroke.  Clin Exp Hypertens. 1996;  18 537-546
    Google Scholar
  • 11 Messerli F H, Mancia G, Conti C R. et al . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients coronary artery disease be dangerous?.  Ann Intern Med. 2006;  144 884-893
    Google Scholar
  • 12 Messerli F H, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension?.  Eur Heart J. 2009;  30 2427-2430
    Google Scholar
  • 13 O’Donell M J, Xavier D, Liu L. et al . Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 Countries (the INTERSTROKE study): a case-control study.  Lancet. 2010;  376 112-123
    Google Scholar
  • 14 Progress Collaborative Group . Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.  Lancet. 2001;  358 1033-1041
    Google Scholar
  • 15 Psaty B M, Lumley T, Furberg C D. et al . Health outcomes associated with various antihypertensive therapies used first line agents: a network meta-analysis.  JAMA. 2003;  289 2534-2544
    Google Scholar
  • 16 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events.  Stroke. 2003;  34 2741-2749
    Google Scholar
  • 17 Rothwell P M, Howard S C, Dolan E. et al . Prognostic significance of visit-to-visit variability, maximun systolic blood pressure, and episodic hypertension.  Lancet. 2010;  375 895-905
    Google Scholar
  • 18 Schrader J, Lüders S, Kulschewski A. et al . Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).  Stroke. 2005;  36 1218-1226
    Google Scholar
  • 19 Schrader J. Blutdrucksenkung nach Schlaganfall.  Dtsch Med Wochenschr. 2006;  131 758-761
    Google Scholar
  • 20 Skoog I, Lernfelt B, Landahl S. et al . 15-year longitudinal study of blood pressure and dementia.  Lancet. 1996;  347 1141-1145
    Google Scholar
  • 21 Tu J V. Reducing the global burden of stroke.  Lancet. 2010;  376 74-75
    Google Scholar
  • 22 Webb A J, Fischer U, Mehta Z, Rothwell P M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.  Lancet. 2010;  375 906-915
    Google Scholar
  • 23 Williams B, Lacy P S, Thom S M. et al . Differential impact of blodd pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.  Circulation. 2006;  113 1213-1225
    Google Scholar
  • 24 Yusuf S, Diener H C, Sacco R L. et al . Telmisartan to prevent recurrent stroke and cardiovascular events.  N Engl J Med. 2008;  359 1225-1237
    Google Scholar
  • 25 Yusuf S, Hawken S, Ôunpuu S. et al on behalf of the INTERHEART study investigatorsE . ffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study.  Lancet. 2004;  364 937-952
    Google Scholar

Prof. Dr. Joachim Schrader

St. Josefs-Hospital

Krankenhausstr. 13

49661 Cloppenburg

Phone: 04471/16-2951

Fax: 04471/16-2970

Email: j.schrader@kh-clp.de

      >